Search Results - Rachel M. Layman

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis by Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Adam Brufsky

    Published in Breast (2025-06-01)
    Get full text
    Article


  2. 2

    Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis by Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M. Layman

    Published in Frontiers in Oncology (2022-07-01)
    Get full text
    Article


  3. 3

    Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer by Hope S. Rugo, Xianchen Liu, Benjamin Li, Lynn McRoy, Rachel M. Layman, Adam Brufsky

    Published in Breast (2023-06-01)
    Get full text
    Article


  4. 4

    Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies by Jason A. Mouabbi, Akshara Singareeka Raghavendra, Roland L. Bassett, Amy Hassan, Debu Tripathy, Rachel M. Layman

    Published in npj Breast Cancer (2022-12-01)
    Get full text
    Article


  5. 5

    Clinical outcomes and Oncotype DX Breast Recurrence Score® in early‐stage BRCA‐associated hormone receptor‐positive breast cancer by Rachel M. Layman, Heather Lin, Angelica M. Gutierrez Barrera, Meghan S. Karuturi, Clinton Yam, Banu K. Arun

    Published in Cancer Medicine (2022-03-01)
    Get full text
    Article


  6. 6

    Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older by Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Hope S. Rugo

    Published in Frontiers in Oncology (2023-09-01)
    Get full text
    Article


  7. 7

    Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer by Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele

    Published in npj Breast Cancer (2022-10-01)
    Get full text
    Article


  8. 8

    A phase Ib/II trial of neoadjuvant neratinib added to standard therapy in patients with HER2-positive or HR-positive/HER2-negative inflammatory breast cancer (including stage III a... by Bora Lim, Angela Marx, Megumi Kai, Angela Alexander, Roland Bassett, Wencai Ma, Jie Willey, Huiming Sun, Azadeh Nasrazadani, Mohammad M. Mohammad, Jianhua Zhang, Anthony Lucci, Susie X. Sun, Michael C. Stauder, Gary J. Whitman, Huong Le-Petross, Vicente Valero, Wendy A. Woodward, Rachel M. Layman

    Published in Therapeutic Advances in Medical Oncology (2025-10-01)
    Get full text
    Article


Search Tools: